MRI Biomarkers and Cediranib Therapy in Mouse Glioma Model
Author Information
Author(s): Christian T. Farrar, Walid S. Kamoun, Carsten D. Ley, Young R. Kim, Ciprian Catana, Seon J. Kwon, Bruce R. Rosen, Rakesh K. Jain, A. Gregory Sorensen
Primary Institution: Massachusetts General Hospital
Hypothesis
How do MRI tumor biomarkers respond to cediranib therapy in a mouse glioma model?
Conclusion
Cediranib therapy significantly increased survival in mice despite no observable changes in tumor volume or some MRI biomarkers.
Supporting Evidence
- Cediranib treatment led to a significant increase in survival despite no change in tumor volume.
- MRI biomarkers showed varied responses to cediranib therapy, indicating the complexity of tumor physiology.
- The study highlights the importance of using multiple biomarkers to assess treatment efficacy.
Takeaway
This study looked at how MRI scans can help us understand if a cancer treatment is working. Even though the treatment didn't change the size of the tumors, it helped the mice live longer.
Methodology
The study used an orthotopic mouse glioma model to assess the response of MRI biomarkers to cediranib treatment, comparing results with histology and optical microscopy.
Potential Biases
Potential biases may arise from the small sample size and the specific mouse model used, which may not fully represent human gliomas.
Limitations
The study's findings may not directly translate to human patients due to differences in tumor biology and treatment responses.
Participant Demographics
Athymic (nu/nu genotype) mice were used in the study.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website